Moderna Stock Plunges Post-Earnings

This is a mRNA. news story, published by Investor's Business Daily, that relates primarily to Moderna news.

mRNA. news

For more mRNA. news, you can click here:

more mRNA. news

Moderna news

For more Moderna news, you can click here:

more Moderna news

stocks trading & speculation news

For more stocks trading & speculation news, you can click here:

more stocks trading & speculation news

Investor's Business Daily news

For more news from Investor's Business Daily, you can click here:

more news from Investor's Business Daily

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best business news, entertainment news, world news, and much more. If you like stocks trading & speculation news, you might also like this article about

Moderna stock

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest stock news, Stocks news, stocks trading & speculation news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

Moderna shares

Investor's Business Daily

•

Business

Business & Economics

Is Moderna stock a buy or a sell? Here's what you need to know

Summary

Nutrition label

76% Informative

Moderna (MRNA) stock took a beating in January after the company slashed its outlook for 2024 and 2025 .

William Blair analyst Myles Minter called Moderna stock a "show-me story" The company is working hard to expand its portfolio.

Moderna 's technology focuses on helping the body create specific messenger RNA , or mRNA.

Despite a promising move after the CDC put out Covid test news, Moderna stock isn't a buy. In fact, shares were definitively a sell on Jan. 13 when they tumbled below their 50-day line. It could take several years for Moderna 's pipeline to really pan out, analysts say. In the meantime, its Covid vaccine has yet to hit a bottom and its RSV vaccine is coming from behind in competition with Pfizer and GSK ( GSK ). Follow Allison Gatlin on X/Twitter at @IBD_AGatlin. YOU MAY ALSO LIKE:.